The Institute supports the drugs use on patients suffering with follicular lymphoma who have previously responded to treatment with MabThera combined with chemotherapy.

Studies have shown that the drug can reduce the spread and growth of cancer by three to four years. MabThera is also approved for use in the treatment of rheumatoid arthritis and chronic lymphocytic leukaemia, as well as non-Hodgkins lymphoma.